Micron Biomedical
PrivateLast Round
Series A
Extension
Jan 16, 2025
Total Funding Raised
$85.1M
Company Overview
Micron Biomedical operates in Healthcare & Life Sciences and is based in Atlanta, Georgia. Its latest recorded funding round was a Series A Extension round in January 2025.
Micron Biomedical is a biopharmaceutical company that develops a proprietary dissolvable microarray patch technology for needle-free delivery of vaccines and therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Micron Biomedical Comparables
Compare Micron Biomedical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Verndari, Inc. | 89% | |
| Vaxess | 87% | |
| Vaxxas | 87% |
For institutional investors. Book with your work email.
Micron Biomedical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 16, 2025 | ||||
| Grant | Jan 14, 2025 | ||||
| Grant | Jan 7, 2025 | ||||
| Grant | Nov 16, 2023 | ||||
| Series A Extension | May 10, 2023 | ||||
Series A | Nov 28, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Micron Biomedical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CEPI | Grant |
| Georgia Research Alliance | Series A |
| Gates Foundation | Grant |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Bill & Melinda Gates Foundation | Grant |
| The Bill & Melinda Gates Foundation Trust | Grant |
| Global Health Investment Corporation | Series A, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2026
Recognized as highest global priority innovation by VIPS Alliance.
- Jan 1, 2026
Named to Fast Company's 2026 World's Most Innovative Companies list.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 28, 2026
Micron Biomedical, Inc. appoints Anand Subramony, Ph.D., as Executive Vice President, Global Product Development and Combination Product Commercialization to lead product development, regulatory strategy, commercialization, and partnership strategy in Georgia on Oct. 28th '26.
- is_developingOct 21, 2026
Under a contract with the CDC, Micron Biomedical, Inc. is to advance development of a novel live-attenuated rotavirus vaccine delivered through the skin in Georgia on Oct. 21st '26.
- expands_facilitiesAug 28, 2026
Micron Biomedical, Inc. expands its commercial-scale manufacturing footprint in Georgia with a recently opened facility supporting its dissolvable microarray vaccines and therapeutics pipeline toward commercialization.
- receives_awardAug 28, 2026
Micron Biomedical, Inc. receives the 2026 Golden Helix Phoenix Award from Georgia Life Sciences during the Georgia Life Sciences Summit in Georgia on Aug 28th '26, recognizing collaborations that exemplify innovation, resilience, and leadership in advancing Georgia’s life sciences ecosystem; CEO Steven Damon and co-founder and Executive Vice President Sebastien Henry accept the award.
- partners_withAug 28, 2026
Micron Biomedical, Inc. and Emory collaborate in Georgia to generate clinical evidence supporting dissolvable microarray technology across multiple vaccine applications as of Aug. 28th '26.
For institutional investors. Book with your work email.
Micron Biomedical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Micron Biomedical's valuation, stock price, and market status.
Is Micron Biomedical a public or private company?
Micron Biomedical is a private company.
What is the current stock price of Micron Biomedical?
Micron Biomedical is a private company, so its shares have no public market price. Caplight tracks Micron Biomedical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Micron Biomedical worth (valuation)?
Valuation information for Micron Biomedical is not publicly available.
Can I buy Micron Biomedical stock?
Micron Biomedical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Micron Biomedical's last funding round?
Micron Biomedical's most recent funding round was Series A Extension on January 16, 2025.
Who are the main investors in Micron Biomedical?
Key investors in Micron Biomedical include Bill & Melinda Gates Foundation, The Bill & Melinda Gates Foundation Trust, Global Health Investment Corporation, J2 Ventures.
Will Micron Biomedical IPO soon?
No public IPO plans have been announced for Micron Biomedical.
How can I track Micron Biomedical secondary market activity?
Caplight tracks bids, offers, and trades in Micron Biomedical's shares on secondary markets.